Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2020 → 2021: -53.61%
Price change 2021 → 2022: -63.67%
Price change 2022 → 2023: 8.97%
Price change 2023 → 2024: -56.80%
Price change 2024 → 2025: 82.54%
Price change 2025 → 2026: 63.19%
Price change 2026 (year to date): 71.91%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Negative or zero equity.
P/E (Price/Earnings)
P/E ratio: -3.56
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 25.87% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="CMPS" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| COMPASS Pathways plc | – | – | – | 🔒 |
| BioGaia AB (publ) | 32.7 | 0.01 | +13.3 % | – |
| Clariane SE | 611.5 | 2.16 | +12.4 % | – |
| Nutex Health, Inc. | 6.9 | 1.07 | +54.6 % | – |
| Gerresheimer AG | 31.7 | 1.48 | +5.6 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Accounts and financial health
Balance sheet and cash flow published by COMPASS Pathways plc over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 273 m | 143 m | 220 m | 165 m | 150 m |
| Total Debt | 3.6 m | 1.9 m | 33.0 m | 32.2 m | 20.9 m |
| Net Debt | -270 m | -141 m | -187 m | -133 m | -129 m |
| Equity | 284 m | 181 m | 226 m | 155 m | -52.8 m |
| Total assets | 301 m | 197 m | 276 m | 214 m | 210 m |
| Operating cash flow | -67.7 m | -105 m | -97.4 m | -119 m | -157 m |
| Investments (capex) | 334,000 | 596,000 | 66,000 | 0 | 0 |
| Free cash-flow | -68.1 m | -106 m | -97.4 m | -119 m | -157 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.
Valuation and competitors
COMPASS Pathways plc compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| COMPASS Pathways plc | 1.3 bn | n/a | 0.0 % |
| MapLight Therapeutics, Inc. MPLT | 309 m | n/a | 0.0 % |
| Rapport Therapeutics, Inc. Common Stock RAPP | 1.3 bn | n/a | 0.0 % |
| Harmony Biosciences Holdings, Inc. HRMY | 2.0 bn | 11.0 | 18.3 % |
| Minerva Neurosciences, Inc. NERV | 115 m | n/a | 0.0 % |
| LB Pharmaceuticals Inc Common Stock LBRX | 1.4 bn | n/a | 0.0 % |
| GH Research PLC GHRS | 1.3 bn | n/a | 0.0 % |
| ACADIA Pharmaceuticals Inc. ACAD | 3.2 bn | 8.4 | 36.5 % |
| Praxis Precision Medicines, Inc. PRAX | 9.2 bn | n/a | 0.0 % |
| Sector median (Nasdaq) | 20.8 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering COMPASS Pathways plc publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in COMPASS Pathways plc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about COMPASS Pathways plc
What is the COMPASS Pathways plc share price?
Latest recorded price: 9.01 USD on 13/11/2026, for a market cap of 1.3 bn USD.
What do analysts say about COMPASS Pathways plc?
Out of 16 analysts: 15 buy or strong buy, 1 hold, 0 sell or strong sell.
Is COMPASS Pathways plc stock eligible for the French PEA?
No: this listing is a depositary receipt (ADR), excluded from the PEA.
How many employees does COMPASS Pathways plc have?
166 full-time employees according to the latest published profile.
Who runs COMPASS Pathways plc?
Kabir Kumar Nath is the company's chief executive.